These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31266712)

  • 1. Autoimmune and non-autoimmune thyroid dysfunction in HCV infected and HCV-HIV co-infected patients before and after interferon alpha therapy: A prospective study.
    Lowenstein A; Fainboim H; Reyes A; Lutzky C; Ameigeiras B; Schroder T; Eugenio Russmann ML
    Endocrinol Diabetes Nutr (Engl Ed); 2020 Apr; 67(4):263-271. PubMed ID: 31266712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hepatitis C virus infection and thyroid diseases].
    Broussolle C; Steineur MP; Bailly F; Zoulim F; Trépo C
    Rev Med Interne; 1999 Sep; 20(9):766-73. PubMed ID: 10522298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10.
    Zhang RW; Shao CP; Huo N; Li MR; Xi HL; Yu M; Xu XY
    World J Gastroenterol; 2015 Sep; 21(33):9765-73. PubMed ID: 26361424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C.
    Pavan MH; Pavin EJ; Gonçales FL; Zantut-Wittmann DE; Wittmann DE
    Braz J Infect Dis; 2011; 15(5):449-56. PubMed ID: 22230851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    Griesbeck M; Valantin MA; Lacombe K; Samri-Hassimi A; Bottero J; Blanc C; Sbihi Z; Zoorob R; Katlama C; Guiguet M; Altfeld M; Autran B;
    AIDS; 2017 Jun; 31(9):1223-1234. PubMed ID: 28492391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
    Bräu N
    Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
    Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
    Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.
    Hsieh MC; Yu ML; Chuang WL; Shin SJ; Dai CY; Chen SC; Lin ZY; Hsieh MY; Liu JF; Wang LY; Chang WY
    Eur J Endocrinol; 2000 May; 142(5):431-7. PubMed ID: 10802518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
    Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy.
    Fernandez-Soto L; Gonzalez A; Escobar-Jimenez F; Vazquez R; Ocete E; Olea N; Salmeron J
    Arch Intern Med; 1998 Jul; 158(13):1445-8. PubMed ID: 9665354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mental disorders in HIV/HCV coinfected patients under antiviral treatment for hepatitis C.
    Martin-Subero M; Diez-Quevedo C
    Psychiatry Res; 2016 Dec; 246():173-181. PubMed ID: 27718466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
    Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients].
    Ke YC; Li LH; Hu FY; Lan Y; He YZ; Chen XJ; Tang XP; Cai WP; Lu RC; He Y; Li HQ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):282-287. PubMed ID: 29996340
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
    Bini EJ; Mehandru S
    Arch Intern Med; 2004 Nov; 164(21):2371-6. PubMed ID: 15557418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group.
    Causse X; Payen JL; Izopet J; Babany G; Girardin MF
    J Hepatol; 2000 Jun; 32(6):1003-10. PubMed ID: 10898321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
    Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; de Mendoza C; Cascajero A; Muñoz F; González-Lahoz J; Benito JM
    Antivir Ther; 2007; 12(4):459-68. PubMed ID: 17668554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
    Bräu N
    J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.